• Propofo L Injection 2%, China (20ml400mg) , Propofo L Injection Manufacturers
  • Propofo L Injection 2%, China (20ml400mg) , Propofo L Injection Manufacturers

Propofo L Injection 2%, China (20ml400mg) , Propofo L Injection Manufacturers

Function: Specialist Drugs, Anesthetic and Adjuvant
Certification: GMP
Grade Standard: Medicine Grade
Type: Injection
State: Liquid
Volatile: Volatile
Customization:
Manufacturer/Factory & Trading Company

360° Virtual Tour

Diamond Member Since 2021

Suppliers with verified business licenses

Guangdong, China
High Repeat Buyers Choice
More than 50% of buyers repeatedly choose the supplier
Experienced Team
The supplier has 12 foreign trading staff(s) and 7 staff(s) with over 6 years of overseas trading experience
Patents Awarded
The supplier had awarded 4 patents, you can check the Audit Report for more information
Quality Assurance
The supplier provides quality assurance
to see all verified strength labels (27)

Basic Info.

Model NO.
20ml: 400mg
Model No.
20ml:400mg
Application
Surgery
Suitable for
Elderly, Adult, Children
Pharmaceutical Technology
Chemical Synthesis
Transport Package
Carton
Specification
20ml: 400mg
Origin
Qingyuan, Guangdong, China
HS Code
3004909099

Product Description

This information is only for medical or pharmacy professionals to read.

Drug Name Generic name: propofo l injectable emulsion Used name propofo l injection
Brand name: Di shi ning English name: propofo l injectable emulsion
Chinese spell: Bingbofen Ruzhuangzhusheye
Ingredients Chemical name: 2,6-Dissoprophylphenol Chemical structure: OH CH3 CH3 H3C H3C Molecular formula: C12H18O Molecular weight: 178.27
Excipients: soybean oil, glycerin, egg yolk lecithin, sodium hydroxide, water for injection

Description: The product is a white, uniform, and lacteal liquid.

Strength 200ml:400mg 

Dosage and Administration The product is only used in the hospital or outpatient treatment room with well-found equipment, and must be used by the doctors trained in anesthesia and intensive care. Continually monitor the breath and circulatory function (e.g. electrocardiogram, oxyhemoglobin saturation) of patients, and facilities for maintenance of a patent airway, providing artificial ventilation and other instituting resuscitation must be immediately available. The product should not be administered by person involved in the conduct of the surgical/diagnostic procedure during the sedation of surgery and diagnostic procedure. According to patient responses and premedication, the administration should be individualized. In general, the product anesthesia is supplemented with analgesic agents.


Anesthesia maintenance Maintain the depth of anesthesia by continual intravenous infusion or repetitive injection of the product. The routine dosage to maintain anesthesia is 4~12 mg/kg per hour calculated by body weight. The maintenance dosage reduces to 4mg/kg per hour calculated by body weight during the minor operation of stress, e.g. minimally invasive surgery. For old people, patients with unstable situation, cardiopulmonary insufficiency, hypovolemia or ASA III-IV, further reduce the dosage of product according to the gravity of patients' illness and the anesthesia technology adopted. The general anesthesia of children over three years Anesthesia induction The product is slowly instilled to conduct anesthesia induction until the clinical signs show the onset of anesthesia. The dosage should be adjusted according to age or body weight. For most of children over 8 years of age, the routine dosage is 2.5mg/kg calculated by body weight while conducting anesthesia induction with the product. For children under 8 years of age, especially children from 1 month through 3 years of age, the required dosage may be higher. (2.5~4mg/kg calculated by body weight) General Anesthesia maintenance Maintain the required level of anesthesia by continual intravenous infusion. There is apparent difference in administration rate of different patients, generally achieve the satisfactory effect of anesthesia .

maintenance under the administration rate of 9~15mg/kg per hour calculated by body weight. For younger children, the required dosage may be higher. For ASA III-IV patients, it is recommended to use the lower dosage (see ATTENTIONS) The sedation at the time of the surgery and diagnosis of adults. 

Pregnant and nursing women use Although animal studies indicate the product has no the teratogenic effect, the product should not be used in pregnancy. The propofo l may cause the newborn inhibition by placental barrier. It is not recommended to use the product in the aspect of obstertrics anesthesia, including abdominal delivery. The studies of lactation women indicate a small amount of propofo l can be excreted in human milk. The nursing women should stop the lactation within 24hrs after using the product. The pregnancy women and obstetric patients must not use the product (excluding abortion patients)

Storage: Preserve in a tightly container at 2~25ºC, do not freeze.
Package: 5 PCS/box or 40boxes /carton
Expiry date: 24 months
Manufacturer Manufacturer name: Guangdong Jiabo Pharmaceutical Co., Ltd.
Manufacturing address: Bio-Pharmaceutical Park, High &New Technology industries development Zone, Qingyuan City, Guangdong Province
 
Website: jiabopharm.en.made-in-china.com

Send your message to this supplier

*From:
*To:
*Message:

Enter between 20 to 4,000 characters.

This is not what you are looking for? Post a Sourcing Request Now

You Might Also Like

Diamond Member Since 2021

Suppliers with verified business licenses

Manufacturer/Factory & Trading Company
Number of Employees
478
Year of Establishment
2003-10-20